Latest Period
Q2 2026
Security Snapshot
RIGEL PHARMACEUTICALS INC - Common Stock, par value $0.001 per share (RIGL) Institutional Ownership
CUSIP: 766559702
13F Institutional Holders and Ownership History from Q2 2024 to Q2 2026
Institutions Reporting
153
Shares (Excl. Options)
16,380,431
Price
$39.12
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- RIGL on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 16,380,431
- Total 13F value
- $640,430,710
- Portfolio coverage rank
- 0%
- Share change
- +351,570
- Value change
- +$30,297,110
- Number of holders
- 153
- Shares outstanding
- 18,681,564
- SEC-reported price per share
- $38.50
- Insider filing price
- $38.50
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RIGL - RIGEL PHARMACEUTICALS INC - Common Stock, par value $0.001 per share is tracked under CUSIP 766559702.
- 153 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 149 to 153 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $431,986,659 to $640,430,710.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 153 institutions filings for Q2 2026.
Security key
766559702
Latest holder period
Q2 2026
13F holders
153
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
RIGL full holder history
RIGEL PHARMACEUTICALS INC SEC filings
RIGEL PHARMACEUTICALS INC company facts
RIGEL PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 766559702:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
RIGL
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 9.9% | +94% | $76,136,715 | +$36,153,855 | 1,843,504 | +90% | Soleus Capital Master Fund, L.P. | 30 Jun 2026 |
| ARMISTICE CAPITAL, LLC | 9% | +29% | $69,053,600 | +$16,189,600 | 1,672,000 | +31% | Armistice Capital, LLC | 30 Jun 2026 |
| BlackRock, Inc. | 7.7% | -22% | $26,340,596 | -$6,978,323 | 1,381,983 | -21% | BlackRock, Inc. | 31 Mar 2025 |
| STATE STREET CORP | 6% | $45,645,858 | 1,091,223 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| MORGAN STANLEY | 0.7% | $3,297,817 | 116,406 | Morgan Stanley | 30 Sep 2025 | |||
| Invesco Ltd. | 0% | $122,918 | 6,449 | Invesco Ltd. | 31 Dec 2024 |
As of 30 Jun 2026, 153 institutional investors reported holding 16,380,431 shares of RIGEL PHARMACEUTICALS INC - Common Stock, par value $0.001 per share (RIGL). This represents 88% of the company’s total 18,681,564 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
71%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10% | 1,939,818 | +9.7% | 0% | $75,885,690 |
| Soleus Capital Management, L.P. | 9.9% | 1,843,504 | +18335% | 2.5% | $72,117,876 |
| ARMISTICE CAPITAL, LLC | 9% | 1,672,000 | +31% | 1.8% | $65,408,640 |
| STATE STREET CORP | 5.6% | 1,039,994 | -7.2% | 0% | $40,684,565 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 785,107 | +2.7% | 0% | $30,713,386 |
| AMERICAN CENTURY COMPANIES INC | 4% | 741,718 | +36% | 0.01% | $29,016,008 |
| LSV ASSET MANAGEMENT | 3.9% | 721,666 | +20% | 0.05% | $28,232,000 |
| ACADIAN ASSET MANAGEMENT LLC | 3.2% | 591,686 | -11% | 0.03% | $23,137,000 |
| D. E. Shaw & Co., Inc. | 2.9% | 542,539 | +22% | 0.01% | $21,224,126 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 483,175 | +9.7% | 0% | $18,906,353 |
| MARSHALL WACE, LLP | 2% | 367,393 | -39% | 0.01% | $14,372,414 |
| CM Management, LLC | 1.3% | 250,000 | +6.4% | 6.2% | $9,780,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3% | 233,728 | +58% | 0% | $9,143,439 |
| DIMENSIONAL FUND ADVISORS LP | 1.2% | 227,951 | -40% | 0% | $8,917,295 |
| GOLDMAN SACHS GROUP INC | 1.2% | 226,780 | -48% | 0% | $8,871,634 |
| TWO SIGMA INVESTMENTS, LP | 1.1% | 207,578 | -49% | 0.01% | $8,120,451 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1% | 195,000 | 0.01% | $7,628,000 | |
| MORGAN STANLEY | 1% | 186,049 | +88% | 0% | $7,278,237 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.83% | 154,627 | -13% | 0% | $6,049,008 |
| NORTHERN TRUST CORP | 0.78% | 146,381 | +8.8% | 0% | $5,726,425 |
| RENAISSANCE TECHNOLOGIES LLC | 0.78% | 145,846 | -57% | 0.01% | $5,705,496 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 0.7% | 131,177 | +4.4% | 0.02% | $5,131,644 |
| AQR CAPITAL MANAGEMENT LLC | 0.67% | 124,801 | +37% | 0% | $4,882,214 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.66% | 124,184 | 0.09% | $4,858,078 | |
| Nuveen, LLC | 0.66% | 123,961 | -63% | 0% | $4,849,354 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Latest
Q2 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 16,380,431 | $640,430,710 | +$30,297,110 | $39.12 | 153 |
| 2026 Q1 | 15,986,079 | $431,986,659 | -$13,467,964 | $27.04 | 149 |
| 2025 Q4 | 16,094,279 | $688,576,820 | +$63,536,235 | $42.83 | 185 |
| 2025 Q3 | 14,989,035 | $424,666,568 | +$32,448,563 | $28.33 | 164 |
| 2025 Q2 | 13,883,445 | $260,032,689 | +$336,299 | $18.73 | 121 |
| 2025 Q1 | 13,902,025 | $250,095,419 | +$32,047,743 | $17.99 | 118 |
| 2024 Q4 | 12,067,467 | $202,977,408 | +$2,514,731 | $16.82 | 114 |
| 2024 Q3 | 11,904,852 | $192,606,131 | +$27,253,219 | $16.18 | 87 |
| 2024 Q2 | 10,378,502 | $85,309,593 | +$85,148,446 | $8.22 | 80 |